AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

NIAID

Toward Defining the Non-HIV Infectious Diseases Leadership Group

Future Directions for NIAID HIV Research

Co-authored by Carole Heilman, Ph.D., Director of NIAID’s Division of Microbiology and Infectious Diseases Over the course of the past two decades the National Institute of Allergy and Infectious Diseases (NIAID) has developed an extensive set of networks to conduct clinical trials related to HIV/AIDS. These networks have helped to develop effective treatments for AIDS,…

Stigma – 30 Years Into the Epidemic

Dr. Anthony Fauci

Our colleague Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID) will appear tonight on "Hope Survives: 30 Years of AIDS," an hour-long special on Anderson Cooper 360° at 9pm ET on CNN. The program will focus on the role stigma continues to play in the spread of HIV, and prevention and…

Which of our Blog Posts and Videos Do YOU View? Looking Back at 2010

Listen:

Javascript and flash are required to play this audio file.

Download MP3
2010

As the AIDS.gov blog's fourth year begins, we at AIDS.gov are taking time to reflect on 2010 and look to the year ahead. As we continue to integrate monitoring and evaluation into our work, we thought that the New Year provided a nice benchmark to look more closely at our blog. For us, the blog…

NIH-Funded Study Finds Daily Dose of Antiretroviral Drug Reduces Risk of HIV

blog.aids.gov

Today, the New England Journal of Medicine published research findings from the iPrEx study funded by the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation testing the efficacy of pre-exposure prophylaxis (PrEP). The study is a major step forward in our ability to prevent new HIV infections. The study found that…

President Obama Welcomes New HIV Prevention Research Results

blog.aids.gov

WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research.  The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…

New Announcement about PrEP from NIH

NIAID

The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.

Future Directions-HIV Clinical Trials-Town Hall

blog.aids.gov

On Tuesday, October 26, more than 300 representatives from our current HIV clinical trial networks, the infectious diseases research community, and HIV advocacy groups attended the “Town Hall Meeting to Examine the Restructuring of the NIAID Clinical Trials Networks.” The goals of the meeting were to: Provide NIAID’s overarching vision for the future of its…

What’s in it for Non-AIDS Infectious Diseases Researchers?

Future Directions for NIAID HIV Research

Co-authored by Hugh Auchincloss, M.D., NIAID Deputy Director and Carole Heilman, Ph.D., Director of NIAID’s Division of Microbiology and Infectious Diseases So far all of the postings on this blog series have been about HIV/AIDS research or about diseases that are major comorbidities. This is appropriate since we have been discussing the upcoming re-competition of…